FindTrial
Sign In

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT06810141
Enrollment
Unknown
Registered
2025-02-05
Start date
Unknown
Completion date
Unknown
Last updated
2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NMIBC

Brief summary

This expanded access protocol is designed to provide Recombinant Mycobacterium BCG (rMBCG) to patients with Non-muscle invasive bladder cancer (NMIBC) who are eligible to receive TICE® BCG, may benefit from its use, and who are ineligible to participate in a clinical trial using rMBCG, or for other reasons cannot participate (eg, geographically unable to access a study site).

Interventions

BIOLOGICALrMBCG

1-19.2e8 colony-forming units (CFU) of rMBCG

Sponsors

ImmunityBio, Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years

Inclusion criteria

Participant Eligibility: Women and men of all races and ethnic groups are eligible for this trial. Inclusion Criteria and Contraindications: Participants must meet the inclusion criteria and contraindications determined by the standards of their institution per the TICE BCG label. In BCG naïve subjects with NMIBC, enrollment should occur only if TICE BCG is unavailable.

Countries

United States

Contacts

CONTACTJayson Garmizo
jayson.garmizo@immunitybio.com310-912-2230

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026